279 related articles for article (PubMed ID: 28710334)
1. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.
Du W; Seah I; Bougazzoul O; Choi G; Meeth K; Bosenberg MW; Wakimoto H; Fisher D; Shah K
Proc Natl Acad Sci U S A; 2017 Jul; 114(30):E6157-E6165. PubMed ID: 28710334
[TBL] [Abstract][Full Text] [Related]
2. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
[TBL] [Abstract][Full Text] [Related]
3. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
4. Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas.
Kanaya N; Kitamura Y; Lopez Vazquez M; Franco A; Chen KS; van Schaik TA; Farzani TA; Borges P; Ichinose T; Seddiq W; Kuroda S; Boland G; Jahan N; Fisher D; Wakimoto H; Shah K
Sci Transl Med; 2023 May; 15(698):eade8732. PubMed ID: 37256936
[TBL] [Abstract][Full Text] [Related]
5. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract][Full Text] [Related]
7. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
[No Abstract] [Full Text] [Related]
8. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
[TBL] [Abstract][Full Text] [Related]
10. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
Leoni V; Gatta V; Palladini A; Nicoletti G; Ranieri D; Dall'Ora M; Grosso V; Rossi M; Alviano F; Bonsi L; Nanni P; Lollini PL; Campadelli-Fiume G
Oncotarget; 2015 Oct; 6(33):34774-87. PubMed ID: 26430966
[TBL] [Abstract][Full Text] [Related]
11. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.
Castelo-Branco P; Passer BJ; Buhrman JS; Antoszczyk S; Marinelli M; Zaupa C; Rabkin SD; Martuza RL
Gene Ther; 2010 Jun; 17(6):805-10. PubMed ID: 20220784
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
[TBL] [Abstract][Full Text] [Related]
14. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
[TBL] [Abstract][Full Text] [Related]
15. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Jahan N; Lee JM; Shah K; Wakimoto H
Int J Cancer; 2017 Oct; 141(8):1671-1681. PubMed ID: 28567859
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.
Chastkofsky MI; Pituch KC; Katagi H; Zannikou M; Ilut L; Xiao T; Han Y; Sonabend AM; Curiel DT; Bonner ER; Nazarian J; Horbinski CM; James CD; Saratsis AM; Hashizume R; Lesniak MS; Balyasnikova IV
Clin Cancer Res; 2021 Mar; 27(6):1766-1777. PubMed ID: 33272983
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers.
Kang KD; Bernstock JD; Totsch SK; Gary SE; Rocco A; Nan L; Li R; Etminan T; Han X; Beierle EA; Eisemann T; Wechsler-Reya RJ; Bae S; Whitley R; Gillespie GY; Markert JM; Friedman GK
Clin Cancer Res; 2022 Dec; 28(24):5419-5430. PubMed ID: 36239623
[TBL] [Abstract][Full Text] [Related]
19. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
Wakimoto H; Kesari S; Farrell CJ; Curry WT; Zaupa C; Aghi M; Kuroda T; Stemmer-Rachamimov A; Shah K; Liu TC; Jeyaretna DS; Debasitis J; Pruszak J; Martuza RL; Rabkin SD
Cancer Res; 2009 Apr; 69(8):3472-81. PubMed ID: 19351838
[TBL] [Abstract][Full Text] [Related]
20. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
